Upcoming clarity around the firm's cancer treatment called cabozantinib could drive upside to estimates, the firm said.
It's time to buy Exelixis shares ahead of readouts on the biotech firm's cancer treatment, according to Wells Fargo. Analyst Derek Archila initiated coverage of Exelixis with an overweight rating, saying the biotech company's consistent revenue growth and upcoming clarity around the firm's cancer product called cabozantinib will drive upside.
mountain Exelixis shares 1-day —CNBC's Michael Bloom contributed to this report.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Miami hosts Cleveland after Mitchell's 40-point gameCleveland visits the Miami Heat after Donovan Mitchell scored 40 points in the Cavaliers' 118-114 overtime win against the Boston Celtics.
Consulte Mais informação »
PennDOT begins repairing potholes on over 40 state roads around PhiladelphiaPennDOT crews rode down I-76 westbound Tuesday, filling highway cavities with a spray patching truck.
Consulte Mais informação »
6 Easy Exercises To Prevent the Dreaded ‘Dad Bod’ After 40A trainer shares six of the easiest exercises to prevent the so-called 'dad bod' that can creep in when you hit your forties.
Consulte Mais informação »
Warriors Observations: Steph Curry's 40 Wasted in Frustrating Loss to ThunderSteph Curry scored 40 points but it wasn’t nearly enough as the Warriors were outplayed in a loss to the Thunder on Tuesday night.
Consulte Mais informação »
China logs nearly 40 million entry-exit trips in two monthsChina logged 39.72 million entry and exit trips between Jan. 8 to March 7, according to National Immigration Administration data, showing the revival in travel after COVID-19 restrictions were dismantled.
Consulte Mais informação »
Fantasy Baseball Rankings 2023: Top 40 first basemenAs in some recent seasons, the first base position is once again a bit top-heavy in 2023. You'd be hard-pressed to find a big star outside the top five or six at the position — but that doesn't mean you're screwed if you don't grab one of the big names.
Consulte Mais informação »